EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 20:58 (447 d 05:27 ago) – Posting: # 20959
Views: 3,742

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
21,357 posts in 4,459 threads, 1,492 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Saturday 02:26 CET (Europe/Vienna)

The way to do research is to attack the facts
at the point of greatest astonishment.    Celia Green

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5